Healthcare Industry News: Novo Ventures
News Release - October 5, 2009
NeuroTherapeutics Pharma Appoints Dr. Corey Goodman to Its Board of DirectorsCHICAGO--(HSMN NewsFeed)--NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced the appointment of Corey S. Goodman, Ph.D., to its Board of Directors.
“Dr. Goodman is a highly respected veteran in the biotechnology industry, and his addition to the NeuroTherapeutics Board will be extremely valuable as we advance our lead compounds in epilepsy, neuropathic and acute pain, and other disorders of the nervous system,” said Dr. Stephen D. Collins, Chief Executive Officer of NeuroTherapeutics Pharma.
Dr. Goodman was most recently President of Pfizer's Biotherapeutics and Bioinnovation Center and a member of its Executive Leadership Team. He previously co-founded Exelixis and was the co-founder, President and CEO of Renovis, which was acquired by Evotec. Dr. Goodman was previously a Professor at Stanford University and U.C. Berkeley, where he served as the Evan Rauch Professor of Neuroscience, the Director and co-founder of the Wills Neuroscience Institute, and an Investigator with the Howard Hughes Medical Institute. Dr. Goodman is an elected member of the National Academy of Sciences and the recipient of the Alan T. Waterman Award, the Gairdner Foundation International Award for Achievement in Medical Sciences, and the March-of-Dimes Prize in Developmental Biology.
“NTP has developed a novel platform with a unique and highly specific mechanism of action. The preclinical efficacy across multiple models is extremely encouraging, and the safety profile looks clean. These data set the stage for a series of clinical candidates which could have tremendous impact for patients, and given the new mechanism, provide a whole new generation of therapeutics. I’m excited to help them,” said Dr. Goodman.
Dr. Heath Lukatch, Chairman of the Board of NeuroTherapeutics, stated, “Dr. Goodman brings tremendous experience in both neuroscience and biotechnology. His advice and guidance will be of great value to the company as NTP begins clinical development of its revolutionary lead compound for the treatment of epilepsy and pain disorders.”
About NeuroTherapeutics Pharma
NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. NTP will file an IND for its lead compound, NTP-2014, in the first quarter of 2010. The compound has exhibited excellent efficacy results in multiple models of epilepsy, chronic neuropathic pain and acute pain. NTP-2014 also has demonstrated a very favorable safety profile in the IND-enabling (GLP) subchronic toxicology studies.
NTP is financially backed by Novo Ventures and Thomas, McNerney and Partners. The company is led by a strong management team with significant drug development experience in the CNS space. Collectively, the team has filed over 15 INDs and has obtained approval for eight NDAs. The company is currently raising its Series B financing, which will advance NTP-2014 through multiple proof-of-concept Phase II trials and further develop a pipeline to expand this new class of therapy. Additional information can be found at the company's website: www.ntprx.com.
Source: NeuroTherapeutics Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.